

The correlation between follicular fluid anti-mullerian hormone levels and fertilization and embryo quality in ART cycles

Abbas Aflatoonian M.D., Mehri Mashayekhy M.D., Farnaz Mohamadian M.D., Fatemeh Mansoori Moghaddam M.D.

Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Received: 24 July 2010; accepted: 30 August 2010

Abstract

Background: Determination of oocyte and embryo quality are one of the most important goals in IVF. Anti-mullerian hormone (AMH) is secreted by the ovarian granulosa cells into blood flow and follicular fluid. Follicular fluid anti-mullerian hormone level is probably a marker of activity of granulosa cells.

Objective: To evaluate whether high level of follicular fluid anti-mullerian hormone level is related to success of fertilization and better embryo quality.

Materials and Methods: 62 women, whose follicular fluid sample was obtained from a single follicle in each patient, underwent IVF with GnRH-agonist long protocol. Based on oocyte fertilization, the patients were divided into fertilized group (n=42) and non-fertilized group (n=20). FF AMH levels were measured in both groups and the quality of embryos was determined in fertilized group.

Results: Median of FF AMH level in fertilized group was higher than that in non-fertilized group (5.7ng/ml v.s. 2.7ng/ml) and a statistically significant difference was observed between the two groups. There was a significant difference between FF AMH level and scores of embryos ($p<0.001$). The medians levels of FF AMH were 6.7ng/ml in good quality embryos and 3.80ng/ml in fair quality embryos.

Conclusion: Our results indicate that FF AMH level has positive correlation with fertilization and embryo quality; therefore, it can be considered as a marker of IVF outcome.

Key words: Anti-mullerian hormone, Follicular fluid, Fertilization, Embryo quality, In-vitro fertilization.

Introduction

Recognition and selection of the best oocyte and embryo can improve IVF outcome. Follicular fluid is composed of substances which are secreted by granulosa cells, theca cells and blood flow. It is a suitable environment for oocyte growth and development. Biochemical characteristics of the follicular fluid play an important role in the prediction of oocyte quality, fertilization and ultimately the embryo quality in noninvasive

methods (1, 2). Anti-mullerian hormone (AMH) is one member of transforming growth factor- β (TGF- β) (2-5). AMH plays a fundamental role in gonadal differentiation during fetal period and inhibits the formation of mullerian ducts in male fetus (2, 6-8). AMH is secreted by the ovarian granulosa cells into blood flow and follicular fluid in adult female, although its concentration is much higher in the follicular fluid (2,4,6). AMH production is independent of FSH and inhibits FSH-induced follicular growth (9-11). It also has a direct autocrine-paracrine effect on the granulosa cells, oocyte function and embryo quality (5, 12-14). Determination of oocyte and embryo quality are one of the most important goals of embryologists in human IVF. Several methods are employed for determining oocyte and embryo quality (1). Follicular fluid anti-mullerian hormone

Corresponding Author:

Mehri Mashayekhy, Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Email: Dr.Mashayekhy@yahoo.com

(FF AMH) level is probably a marker of the qualitative and quantitative activity of granulosa cells (13). Although some studies have showed the relationship between the level of serum AMH, and quality of oocyte and embryo (9, 11, 12), there are few studies about the relationship existing between these factors and FF AMH level (13). Our study was designed to investigate the association between FF AMH level and successful fertilization and embryo quality in IVF cycles. Based on FF AMH level, we can choose one or two embryos of high viability and thus improve IVF outcome.

Materials and methods

The study was conducted at a reproduction center affiliated to a medical university between February and January 2009. A total of 62 infertile patients, who underwent IVF, participated in this prospective study. The inclusion criteria were: female age <35 years old, presence of both ovaries in ultrasonography, BMI <25 kg/m², day 3 FSH<10 IU/ml, and the duration of menstrual cycle between 25-35 days. Patients with PCOD, history of pelvic surgery, endometriosis, endocrine disorders and couples with male factor who were candidate for ICSI (patients with immotile sperm, azospermia, normal morphology of sperm<4% and frozen-thawed sperms) (15) were not enrolled in this study. Also, patients whose follicular fluid was bloody during the oocyte retrieval were excluded from the study. Before initiating the treatment, venipuncture for assay of FSH, estradiol (E2), and transvaginal ultrasound scan were also performed on the third day of the menstrual cycle.

This study was approved by the ethics committee of Research and Clinical Center for Infertility affiliated to Shahid Sadoughi University of Medical Sciences. Furthermore, all patients were required to sign a written consent before the initiation of the treatment cycles.

Assay

All transvaginal ultrasonographic evaluations were performed by a single investigator, using a conventional two-dimensional ultrasound (HS-400, Honda, Japan) equipped with a 7.5 MHz vaginal transducer. FSH concentrations were measured by competitive immunoassay (IDCS, Korbach, Germany), intra-assay and inter-assay coefficients of variation were 6% and 6.8% respectively. E2 concentrations were measured using an enzyme-immunoassay kit (DRG, Marburg, Germany), intra-assay and inter-assay coefficients of variation proved to be 6.3% and 6.4% respectively. Measurement of FF AMH levels was performed using AMH/MIS enzyme-linked immunosorbent

assay kit (Beckman Coulter Immunotech Com., Fullerton, CA).

Treatment protocol

All of the patients were treated with a long protocol for ovarian stimulation. For pituitary suppression, the patients were treated with daily administration of 0.5 mg/day buserelin SC (Superfact, Aventis, Frankfurt, Germany) which started in the luteal phase of menstrual cycle. When desensitization was occurred, as evidenced by plasma E₂ levels of ≤50 pg/ml and the absence of ovarian cyst on transvaginal ultrasound examination, buserelin was reduced to 0.25 mg/day and continued until the day of hCG administration. The COH (controlled ovarian hyperstimulation) was initiated with recombinant FSH (Gonal F, Serono, Aubonne, Switzerland) or HMG (Menogon, Ferring, Pharmaceuticals, Germany) 150 IU/day on the day 2 of menstrual cycle. Ovarian response was monitored by serial ultrasound examinations and the evaluation of serum E₂ levels, then gonadotropin doses adjustment was done as required. Urinary human chorionic gonadotropin (Pregnyl, Organon, Oss, the Netherlands) 10000 IU was administered when at least three follicles reached a mean diameter of 18mm.

Oocyte retrieval was performed by the transvaginal ultrasound guided approach, 34-36 hours after the hCG injection. Each patient's follicular fluid sample was collected from one follicle with a diameter greater than 17 mm. Only the first follicle of ovary was selected and the needle was washed before the puncture of the remaining follicles. Follicular fluid of the first selected follicle was separated from the cumulus-oocyte complex and then was centrifuged.

Each of the centrifuged follicular fluid was freezed at -80°C until the samples were all completed. Then, the AMH level of every respective follicular fluid was measured and conventional IVF was performed specifically on the oocyte obtained from the follicular fluid in a separate culture dish. The fertilization of each oocyte was assessed using a microscope 18-20 hours following IVF and the fertilization was confirmed through pronuclei detection. Also the quality of embryo was determined in fertilized oocyte 48 hours after IVF and was scored based on the shape, number and fragmentation of blastomers (16). Score ≥18 was decided to indicate good quality, 15-17 fair quality and <15 poor quality in our center. Based upon fertilization of oocytes, the patients were divided into two groups. Patients with fertilized oocytes were defined as group I and non-fertilized oocytes as group II. FF AMH level and quality of embryos were compared in both groups.

Statistical analysis

The parameters relevant to demographic and COH characteristics were presented based on mean±SD, median and range. The Statistical Package for Social Sciences (SPSS, version 15.0 for windows, SPPS Inc., Chicago, IL) was utilized for data analysis. Normality was assessed using Kolmogorov-Smirnov test.

T-test, Mann-whitney and Chi-square test were used for analysis as needed. To determine the relationship between the score of embryos and the concentration of FF AMH, Kruskal-Wallis test was employed. P-value of less than 0.05 was considered to be statistically significant.

Results

62 infertile patients underwent IVF and 62 oocytes retrieved, of which 42 oocytes were

fertilized (group I) and 20 oocytes were not fertilized (group II). There was no significant difference between fertilized and non-fertilized groups regarding age, infertility duration, BMI, basal FSH, basal E2, duration of stimulation, doses of the administrated gonadotropin, and the E2 level on the day of hCG administration (Table I). Infertility etiology distribution was similar in both groups (Table II). Medians of FF AMH level were 5.7 ng/ml (IQ=3) in fertilized group and 2.7 ng/ml (IQ=1.7) in non-fertilized group. The level of AMH in group I was significantly higher than that in group II ($p<0.001$). There was a significant difference between FF AMH level and embryo scores ($p<0.001$). The medians of FF AMH level were 6.7ng/ml (IQ=5.05) in good quality embryos and 3.80ng/ml (IQ=3.32) in fair quality embryos. No poor quality embryos were detected in this study.

Table I. Comparison of the patient's characteristics in fertilized and non-fertilized groups.

	* Group I (n=42)	** Group II (n=20)	p-value
Age (years)	29.60±4.30	28.70±4.2	0.481
BMI (kg/m ²)	22.20±2	21.30±1.	0.085
Day 3 FSH (mIU/ml)	5.80±2.10	5.90±2.20	0.988
Day 3 E ₂ (pg/ml)	39.60±17.50	39.90±22	0.967
Infertility duration (years)	7.90±4.40	7.20±3.90	0.548
Duration of stimulation (days)	11.20±1.88	11.50±2.67	0.678
Dose of gonadotropin (No.amp)	24.18±6.80	27.26±7.80	0.123
E ₂ on day hCG (pg/ml)	1712	1082	0.058

E₂ , estradiol *Fertilized group **Non – fertilized group

Table II. Etiology of infertility in fertilized and non-fertilized groups.

Etiology	* Group I (n=42)	** Group II (n=20)
Male factor	44.2%	52.6%
Tubal factor	27.9%	21.1%
Unexplained	20.9%	26.3%
Mixed	7%	0%

P =0.586 *fertilized group **Non-fertilized group

Discussion

In the present study, the correlation between FF AMH level and fertilization, and embryo quality was investigated. According to the findings of this study, FF AMH level in fertilized group was higher than that in non-fertilized group and there was a significant difference between the two groups in this regard. Also, the FF AMH level was significantly higher in good quality embryos.

Similarly, Takahashi *et al* investigated FF AMH level in patients who had undergone IVF. Their study indicated that the concentration of FF AMH in fertilized group was higher than that in non-fertilized group. They concluded that FF AMH level proves to be an important indicator of fertilization (17). Mashiach *et al* reported a positive relationship between FF AMH level and

embryo quality in women who had undergone IVF. Mashiach's study was performed on PCOD women while our study was done on women with normal menstrual cycles (18). Jancar *et al* also showed that FF AMH level in modified natural cycles were higher than those in COH cycles. In contrast with our results, they found no significant difference between AMH level and embryo quality in modified natural cycles (19). One reason for the differences in correlation between FF AMH level and embryo quality in different studies is probably the variety of embryo scorings in IVF centers. In two studies, FF AMH level was significantly higher in women who were conceived with IVF (20, 21). Fanchin's investigation failed to find any significant difference between FF AMH level and embryo scores. However, they showed that higher FF AMH level was associated with higher implantation rate (20). Cupisti and Lee's studies

found no correlation between the number of follicles and retrieved oocytes with FF AMH level (22, 23). We were not able to prove the existence of any such relationship because we had selected only one follicle in each patient.

Conclusion

Our results indicate that there exists a positive correlation between FF AMH level and fertilization, and embryo quality. Therefore, we can make use of FF AMH level as an indicator in IVF outcome.

Acknowledgement

The authors are grateful to Farimah Shams for her assistance in statistical analysis and the laboratory staff of the Research and Clinical Center for Infertility for their assistance.

References

- Revelli A, Delle Piane L, Casano S, Molinari E, Massobrio M, Rinaudo P. Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics. *Reprod Biol Endocrinol* 2009; 7: 40.
- Knight P, Glister C. TGF- β superfamily members and ovarian follicle development. *Reproduction* 2006; 132: 191-206.
- La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Arsenio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). *Hum Reprod Update* 2010; 16: 113-130.
- Gruijters MJ VJ, Durlinger AL, Themmen AP. Anti-Müllerian hormone and its role in ovarian function. *Mol Cell Endocrinol* 2003; 211: 85-90.
- Das M, Gillott DJ, Saridogan E, Djahanbakhch O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. *Hum Reprod* 2008; 23: 2122-2126.
- La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. Anti-Mullerian hormone (AMH): what do we still need to know? *Hum Reprod* 2009; 24: 2264-2275.
- Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. *Mol Hum Reprod* 2004; 10: 77-83.
- Vigier B, Picard JY, Tran D, Legeai L, Josso N. Production of anti-Mullerian hormone: another homology between Sertoli and granulosa cells. *Endocrinology* 1984; 114: 1315-1320.
- Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. *Hum Reprod* 2005; 20: 3178-3183.
- Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. *Hum Reprod* 2005; 20: 923-927.
- Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. *Hum Reprod* 2006; 21: 2022-2026.
- Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. *Hum Reprod* 2006; 21: 159-163.
- Feyereisen E, Mendez Lozano DH, Taieb J, Hesters L, Frydman R, Fanchin R. Anti-Mullerian hormone: clinical insights into a promising biomarker of ovarian follicular status. *Reprod Biomed Online* 2006; 12: 695-703.
- Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. *Hum Reprod* 2003; 18: 2368-2374.
- A Rajasekaran RJ. Male Infertility - current trends in the management of azoospermia and oligoasthenoteratozoospermia In: Rao KA. The Infertility Manual. 3rd Ed. New Dehli: Jitendar P Vij; 2009; pp. 179 - 186.
- Depa-Martynow M, Jedrzejczak P, Pawelczyk L. Pronuclear scoring as a predictor of embryo quality in in vitro fertilization program. *Folia Histochem Cytobiol* 2007; 45 (Suppl 1): S85-89.
- Takahashi C, Fujito A, Kazuka M, Sugiyama R, Ito H, Isaka K. Anti-Mullerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization. *Fertil Steril* 2008; 89: 586-591.
- Mashiach R, Amit A, Hasson J, Amzalag S, Almog B, Ben-Yosef D, et al. Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome. *Fertil Steril* 2010; 93: 2299-2302.
- Jancar N, Virant-Klun I, Bokal EV. Serum and follicular endocrine profile is different in modified natural cycles than in cycles stimulated with gonadotropin and gonadotropin-releasing hormone antagonist. *Fertil Steril* 2009; 92: 2069-2071.
- Fanchin R, Mendez Lozano DH, Frydman N, Gougeon A, di Clemente N, Frydman R, et al. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. *J Clin Endocrinol Metab* 2007; 92: 1796-1802.
- Wunder DM, Guibourdenche J, Birkhauser MH, Bersinger NA. Anti-Mullerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection. *Fertil Steril* 2008; 90: 2203-2210.
- Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H, et al. Correlations between anti-mullerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes. *Eur J Med Res* 2007; 12: 604-608.
- Lee JR, Kim SH, Kim SM, Jee BC, Ku SY, Suh CS, et al. Follicular fluid anti-Mullerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles. *Fertil Steril* 2008; 89: 860-867.

